I know there have been many discussions here on the potential link between insulin resistance in Type II Diabetes and PD. I am revisiting the topic after seeing this very recent article abstract stating that there is growing evidence that AD is a metabolic disorder resulting in protein misfolding andneurodegeneration. Research in PD is showing a parallel.


Brain metabolic dysfunction at the core of Alzheimer's disease.

Parkinson's disease, insulin resistance and novel agents of neuroprotection.

It is interesting that two drugs used to treat Type II Diabetes have been in PD clinical trials.

-Laura

If it walks like a duck, quacks like a duck and looks like a duck, well...........

There is no doubt that links have been found and I would have to believe that something common is happening in the cellular pathways.

Your post is timely in that they begin recruiting today for the follow-up Exenatide (Byetta) study. It's funded by MJFF (the first study was funded by The Cure Parkinson's Trust). I think it's just the London study right now, but there may also be a US based study recruiting soon. The Pioglitazone (Actos) study has been recruiting, albeit slowly, for a while now. Too many side effects for many who have looked into it. I'm hoping that we'll get volunteers quickly for the studies as it's a 60 week study.

I would like to hear if Olsen has any thoughts on this topic...

Thanks,

Gary